Once-Daily Doxycycline Formulation for Anti-Inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current doxycycline treatments for conditions like periodontal disease and acne require multiple daily dosing, leading to patient compliance issues and undesirable side effects due to antibiotic properties, while existing formulations do not effectively achieve the desired anti-collagenase and anti-inflammatory effects without antibacterial activity.
Innovation Solution
A once-daily pharmaceutical composition of doxycycline with a combination of immediate release (IR) and delayed release (DR) components, formulated to maintain steady-state blood levels between 0.1 and 1.0 μg/ml, avoiding the antibacterial effects by using a ratio of 75:25 IR:DR, allowing for effective treatment of conditions like periodontal disease and rosacea without the side effects of long-term antibiotic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple daily dosing of doxycycline is used to achieve therapeutic effects, then the anti-collagenase and anti-inflammatory effects are improved, but patient compliance deteriorates and side effects increase
Solution Approach 1:
The doxycycline dosage is divided into immediate release and delayed release components, with the delayed release portion providing extended therapeutic coverage to enable once-daily dosing while maintaining effective blood levels throughout the day
Solution Approach 2:
The formulation uses a dynamic release profile where 75% of the drug releases immediately and 25% releases delayed, creating an optimized blood concentration curve that maintains therapeutic levels without requiring multiple daily doses
2Reliability
If conventional doses of doxycycline are administered to achieve antibiotic effects, then bacterial infection is treated, but undesirable side effects such as reduction of healthy biotic flora and antibiotic resistance increase
Solution Approach 1:
The patent uses sub-antimicrobial doses of doxycycline (below the threshold required for antibiotic activity) while achieving anti-collagenase and anti-inflammatory effects through optimized release kinetics and dosage formulation
Solution Approach 2:
The formulation extracts and isolates the therapeutic benefits of doxycycline (anti-collagenase and anti-inflammatory effects) while eliminating or minimizing the harmful antibiotic effects by using doses below the antimicrobial threshold
3Object-affected harmful factors
If sub-antimicrobial doses of doxycycline are used to avoid side effects, then healthy biotic flora is preserved, but achieving sufficient steady-state blood levels for therapeutic effect becomes difficult
Solution Approach 1:
The dynamic release profile with 75% immediate release and 25% delayed release creates an optimized pharmacokinetic curve that achieves and maintains therapeutic blood levels throughout the day from a single sub-antimicrobial dose
Solution Approach 2:
The immediate release component provides initial rapid absorption to quickly achieve therapeutic blood levels, while the delayed release component sustains these levels throughout the day, ensuring continuous therapeutic effect from a single dose
Data Source
AI summary
Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.